The European Medicines Agency is starting to review the safety of five EU-approved Janus kinase (JAK) inhibitors that are used to treat chronic inflammatory disorders, due to concerns over an increased risk of developing a cardiovascular problem and cancer.
The safety review will focus on Xeljanz (tofacitinib) and Cibinqo (abrocitinib), both from Pfizer, and Jyseleca (filgotinib), Olumiant (baricitinib)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?